Table 2 Financial barriers, facilitators and incentives to CDM development by group of participants
Patients | Physicians | Nursing staff | Pharmacists | Health insurers | DPH | Companies proposing CDM prog. | ||
|---|---|---|---|---|---|---|---|---|
Barriers | Who can pay for CDM | x | x | x | x | x | x | x |
Costs increasing with CDM development | x | x | ||||||
Cost decreasing in HMO due to risk selection | x | x | ||||||
Lack of motivation of health insurer to reimburse CDM | x | x | x | |||||
Facilitators | Proofs of cost-effectiveness of CDM | x | x | x | x | x | ||
Reimbursement of CDM components by health insurance companies adopting long term vision | x | x | x | x | ||||
Costs decreasing with CDM development | x | x | x | |||||
Cost stability | x | x | x | x | ||||
Incentive | Better risk compensation scheme to motivate health insurances to reimburse CDM | x | x | x |